Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly

European Journal of Endocrinology

Volumn 141, Issue 6, 1999, Pages 590-594

  Turner, H E ^a   Lindsell, D R M ^b   Vadivale, A ^a   Thillainayagam, A V ^c   Wass, J A H ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GALLBLADDER CONTRACTION; GALLBLADDER EMPTYING; GALLBLADDER FUNCTION; GALLBLADDER MOTILITY; GALLSTONE FORMATION; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0033375320     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410590     Document Type: Article

References (28)

1. Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Archives of Internal Medicine 1991 151 1573-1578.
2. Morange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus FT et al. Slow release lanreotide treatment in acromegalic patients previously normalised by octreotide. Journal of Clinical Endocrinology and Metabolism 1994 79 145-151.
3. Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
4. Al-Maskari M, Gebbie J & Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical Endocrinology 1996 45 415-421.
5. Giusti M, Gussoni G, Cuttica CM, Giordano G & the Italian Multicenter Slow-Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six month report on an Italian multicenter study. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
6. Caron P, Morange-Romas I, Cogne M & Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism 1997 82 18-22.
7. Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C et al. Sandostatin LAR in acromegalic patients: long term treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 23-28.
8. Davies PH, Stewart SE, Lancranjan I, Sheppard MC & Stewart PM Long-term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly. Clinical Endocrinology 1998 48 311-316.
9. Dowling RH, Hussaini SH, Murphy GM, Besser GM & Wass JAH Gallstones during octreotide therapy. Metabolism 1992 41 22-33.
10. Eastman RC, Arakaki RF, Shawker T, Schock R, Roach P, Comi RJ et al. A prospective examination of octreotide gall-bladder changes in acromegaly. Clinical Endocrinology 1992 36 265-269.
11. Trendle MC, Moertel CG & Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumours. Cancer 1997 79 830-834.
12. Redfern JS & Fortuner WJ. Octreotide biliary tract dysfunction and gallstone formation: pathophysiology and management. American Journal of Gastroenterology 1995 90 1042-1052.
13. Calnach SM, Anderson JV, Fairclough PD, Trembath RC, Wilson PAJ, Parker E et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993 34 270-273.
14. Stolk MF, van Erpecum KJ, Koppeschaar HP, Samsom M, Smout AJ, Akkermans LM et al. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility and motilin release in acromegaly. Gut 1995 36 755-760.
15. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996 38 775-783.
16. Mitsukawa T, Takemura J, Nishizono F, Nakatsuru K, Ohgo S & Matsukura S. Effects of atropine, proglumide, and somatostatin analogue ((SMS 201-995) on bombesin-induced octreotide contraction and CCK secretion in humans. American Journal of Gastroenterology 1989 84 1371-1374.
17. Hopman WP, Van Liessum PA, Pieters GF, Jansen JB, Lamers CB, Smals AG et al. Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment. Digestive Diseases 1992 37 1685-1690.
18. van Liessum PA, Hopman WP, Pieters GF, Jansen JB, Smals AG, Rosenbusch G et al. Postprandial gall bladder motility during long term treatment with the long-acting somatostatin analog SMS-201-995 in acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 69 557-562.
19. Ewins DL, Javaid A, Coskeran PB, Shah S, Butler J, Deprez PH, Miell J et al. Assessment of gallbladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly. Quarterly Journal of Medicine 1992 83 295-306.
20. Erlinger S, Chanson P, Dumont M, Ponsot P, Warnet A & Harris AG. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study. Digestive Diseases 1994 39 2384-2388.
21. Montini M, Gianoloa D, Pagani MD, Perdroncelli A, Caldara R, Gherardi F et al. Cholelithiasis and acromegaly: therapeutic strategies. Clinical Endocrinology 1994 40 401-406.
22. Tauber JP, Poncet MF, Harris AG, Barthel HR, Simonetta-Chateauneuf C, Buscail L et al. The impact of continuous infusion of octreotide on gallstone formation in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1995 80 3262-3266.
23. Avila NA, Shawker TH, Roach P, Bradford MH, Skarulis MC & Eastman R. Sonography of gall bladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course. Journal of Clinical Ultrasound 1998 26 289-294.
24. Stolk MF, van Erpecum KJ, Koppeschaar HP, de Bruin WI, Jansen JB, Lamers CB et al. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly. Gut 1993 34 808-813.
25. Rhodes M, James RA, Bird M, Clayton B, Kendall-Taylor P & Lennard TW. Gall bladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermobility on cessation of treatment. Scandinavian Journal of Gastroenterology 1992 27 115-118.
26. Shi YF, Zhu XF, Harris AG, Zhang JX & Deng JY. Restoration of gall bladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients. Acta Endocrinologica 1993 129 207-212.
27. Gillis JC, Noble S & Goa KL. Octreotide long-acting release (LAR). Drugs 1997 53 681-699.
28. Turner HE, Vadivale A, Keenan J & Wass JAH. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology 1999 51 275-280.